<DOC>
	<DOCNO>NCT00889707</DOCNO>
	<brief_summary>The purpose study determine whether PRX302 safe effective treatment moderate severe Benign Prostatic Hyperplasia ( BPH ) .</brief_summary>
	<brief_title>Transperineal Intraprostatic Injection PRX302 Under Ultrasound Guidance Management Prostatic Hyperplasia</brief_title>
	<detailed_description>This randomize , double-blinded , placebo-controlled study transperineal intraprostatic injection PRX302 sonographic guidance . Subjects randomly assign two treatment group ratio 2:1 PRX302 Placebo , stratify prostate size baseline IPSS .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>Males age 40 80 year ; Lower urinary tract symptom ( LUTS ) , frequency , nocturia , urgency , weak urine stream , hesitancy , intermittency postvoid dribble attributable BPH least 6 month prior dose ; Untreated , intolerant refractory αblockers ; receive medication least 2 week prior screen 4 week prior dose ; Subjects PSA value 4 10 ng/mL assess medical record check ( e.g . biopsy report ) rule presence prostate cancer ; Untreated , intolerant intolerant 5α reductase inhibitor AND must medication least 6 month prior dose ; IPSS 15 high ; Prostate volume screen estimate 30 100 mL determine TRUS ; Provided write Informed Consent participation study . Maximum urine flow rate ( Qmax ) great 12 mL/sec ; Inability void least 150 mL urine ; Post void residual urine volume ( PVR ) great 200 mL ; Subjects unable stand void ; Subjects acute chronic bacterial prostatitis ; Using drug ( e.g . estrogen , androgen ) produce androgen depression anabolic steroid ; Penile prosthesis artificial urinary sphincter ; Presence prostatic cyst large 1 cm diameter ; Unwilling use condom 3 week posttreatment prevent pregnancy avoid semen contact partner ( ) ; Urethral stricture disease ; Bladder neck abnormalities/strictures ; Significant median lobe hyperplasia contribute outflow obstruction ; Confirmed suspect neurogenic bladder dysfunction ; Systemic neurological disorder may affect void function ; Previous pelvic surgery , trauma radiation ; Active genitourinary infection within 7 day screen ; Significant renal dysfunction ( evidence serum creatinine &gt; 1.6 mg/dL screen laboratory evaluation ) ; Abnormal liver function evidence follow abnormal laboratory value great 1.5 upper limit normal ( ULN ) screening : alkaline phosphatase ( ALP ) ; total bilirubin ; alanine transferase ( ALT ) ; and/or aspartate aminotransferase ( AST ) ; Abnormal Prothrombin Time ( PT &gt; 13 sec ) / International Normalized Ratio ( INR &gt; 1.2 ) ; Severe cardiovascular hepatic disease ( American Society Anesthesiologists [ ASA ] &gt; 3 ) ; Presence suspect confirmed malignancy nonmelanomatous , cutaneous malignancy undergo curative intervention ; Receiving anticoagulant ( Subjects receive anticoagulant may enrol discontinuation anticoagulant therapy return INR level within normal limit ( INR &lt; 1.2 ) dose day . Subjects receive platelet inhibitor ( include garlic ) must inhibitors least 6 day . Subjects unable discontinue anticoagulant therapy may enrol study ) ; Subjects receive treatment BPH αblockers , 5α reductase inhibitor phytotherapy ; Subjects take αblockers phytotherapy within 2 week screen 4 week dose ; Subjects receive 5α reductase inhibitor within 6 month dose ; Subjects take part experimental program prior start study study period ; Any medical , psychological condition medical history subject , opinion Investigator Sponsor 's Medical Monitor , unduly increase risk subject 's participation would unnecessarily confound data collect study ; Unable unwilling comply requirement protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>Enlarged Prostate</keyword>
</DOC>